Szegezdi E - Search Results

1

Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells.

Alizadeh Zeinabad H, Yeoh WJ, Arif M, Lomora M, Banz Y, Riether C, Krebs P, Szegezdi E. Alizadeh Zeinabad H, et al. Among authors: szegezdi e. Biomaterials. 2023 Jul;298:122126. doi: 10.1016/j.biomaterials.2023.122126. Epub 2023 Apr 15. Biomaterials. 2023. PMID: 37094524 Free article.

2

TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems.

Alizadeh Zeinabad H, Szegezdi E. Alizadeh Zeinabad H, et al. Among authors: szegezdi e. Cancers (Basel). 2022 Oct 19;14(20):5125. doi: 10.3390/cancers14205125. Cancers (Basel). 2022. PMID: 36291908 Free PMC article. Review.

3

Macromolecular crowding in the development of a three-dimensional organotypic human breast cancer model.

Shologu N, Gurdal M, Szegezdi E, FitzGerald U, Zeugolis DI. Shologu N, et al. Among authors: szegezdi e. Biomaterials. 2022 Aug;287:121642. doi: 10.1016/j.biomaterials.2022.121642. Epub 2022 Jun 16. Biomaterials. 2022. PMID: 35724540 Free article.

4

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.

Gurney M, Stikvoort A, Nolan E, Kirkham-McCarthy L, Khoruzhenko S, Shivakumar R, Zweegman S, Van de Donk NWCJ, Mutis T, Szegezdi E, Sarkar S, O'Dwyer M. Gurney M, et al. Among authors: szegezdi e. Haematologica. 2022 Feb 1;107(2):437-445. doi: 10.3324/haematol.2020.271908. Haematologica. 2022. PMID: 33375774 Free PMC article.

5

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells.

Baev DV, Krawczyk J, O׳Dwyer M, Szegezdi E. Baev DV, et al. Among authors: szegezdi e. Leuk Res Rep. 2014 Sep 1;3(2):79-82. doi: 10.1016/j.lrr.2014.06.001. eCollection 2014. Leuk Res Rep. 2014. PMID: 25379408 Free PMC article.

6

Guiding the Killer and Bringing in Accomplices: Bispecific Antibody Treatment for Malignant Melanoma.

Szegezdi E, Leverkus M. Szegezdi E, et al. J Invest Dermatol. 2016 Feb;136(2):362-364. doi: 10.1016/j.jid.2015.12.002. J Invest Dermatol. 2016. PMID: 26802233 Free article.

7

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.

Dijk Mv, Murphy E, Morrell R, Knapper S, O'Dwyer M, Samali A, Szegezdi E. Dijk Mv, et al. Among authors: szegezdi e. Cancers (Basel). 2011 Mar 15;3(1):1329-50. doi: 10.3390/cancers3011329. Cancers (Basel). 2011. PMID: 24212664 Free PMC article.

8

Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities.

O'Reilly E, Zeinabad HA, Szegezdi E. O'Reilly E, et al. Among authors: szegezdi e. Blood Rev. 2021 Nov;50:100850. doi: 10.1016/j.blre.2021.100850. Epub 2021 May 12. Blood Rev. 2021. PMID: 34049731 Free article. Review.

9

Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testing.

Dhami SPS, Kappala SS, Thompson A, Szegezdi E. Dhami SPS, et al. Among authors: szegezdi e. Drug Discov Today. 2016 Sep;21(9):1464-1471. doi: 10.1016/j.drudis.2016.04.019. Epub 2016 Apr 27. Drug Discov Today. 2016. PMID: 27130156 Review.

10

Targeting AML through DR4 with a novel variant of rhTRAIL.

Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O'Reilly A, Reeve J, Cool RH, O'Dwyer M, Knapper S, Serrano L, Quax WJ, Samali A. Szegezdi E, et al. J Cell Mol Med. 2011 Oct;15(10):2216-31. doi: 10.1111/j.1582-4934.2010.01211.x. J Cell Mol Med. 2011. PMID: 21070598 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page